World's largest vaccine company says bird flu vaccine research and development breakthrough

the world's largest influenza vaccine research and development andmanufacturersSanofi Pasteur experts told reporters in Lyon, France, its latest development of adjuvant influenza vaccine, when the lowest antigen content, the H5N1 virus can still produce a high level of immune response, the vaccine is also by far the lowest dose of H5N1 antigen doseThis means that Sanofi Pasteur was able to produce hundreds of millions of vaccine products at the time of the H5N1 avian influenza outbreakThis is a major breakthrough in the development of the global influenza vaccineAccording to reports, the above results are based on a clinical trial completed in Belgium, a total of 266 18 to 40 years of agehealthadults participated in this trial, the vaccine used for The H5N1 inactivated vaccine, the vaccine added adjuvant substances to improve the body's immune system response level to the vaccine, the adjuvant is Sanofi Pasteur's latest patented technologySanofi Pasteur executives say the World Health Organization will produce high-quality vaccine products in the shortest possible time and in the shortest possible time once the World Health Organization confirms an outbreak of h5N1Sanofi Pasteur's current influenza pandemic vaccine targets all h5N1 strains already identified by the World Health Organization and authoritative experts, and the H5N1 virus is considered the most likely culprit of a global flu pandemicThe World Health Organization predicts that the next pandemic, if it strikes, is likely to result in 1 to 2 million hospitalizations and 28 to 650,000 deaths in countries with more industrialized levels aloneThe damage caused by the influenza pandemic in developing countries would be even more catastrophicSanofi Pasteur, the world's largest manufacturer of seasonal influenza vaccine sourcing and, has
the largest share of the global influenza vaccine market and is headquartered in Lyon, France